65,437 trials
Carcinoma, Non-Small-Cell Lung
Primary: Number of Patients Experiencing Dose Limiting Toxicity (DLT) in Cycle 1 — 2; 0; 2; 1 Participants
Respiratory Syncytial Virus
Primary: Time-Weighted Average Change in Nasal Respiratory Syncytial Virus (RSV ) Viral Load From Baseline (Day 1) to Day 9 — -1.26; -0.91 log10 copies/mL — p=0.040
Sickle Cell Disease · Thalassemia · Diamond-Blackfan Anemia
Primary: Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT) — 3 Participants
Arthritis · Rheumatoid · High Dose
Primary: Number of Participants With Treatment-Related Adverse Events — 608 Participants
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease — 383.6; 339.1 Titers
Skin to Skin Contact in Cesarean Deliveries
Primary: Maternal Evoked Pain Scores — 43.55 units on a scale
Advanced Cancer
Primary: Recommended Dose and Schedule for Phase 2 Studies — 8 mg/m^2/day
Asthma · Communication
Primary: Change in Asthma Control at One Year — -0.42; -0.11 units on a scale
Healthy
Primary: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) — 11.549; 11.981 nanomole hour per liter (nmol·h/L)
Chronic Obstructive Pulmonary Disease
Primary: Mean Night-time Blood Oxygenation — 89.59; 90.04 Percent Oxygenation — p=0.2419
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-∞)] of LY2835219 and ¹³C₈-LY2835219 — 3730; 15.4 nanogram*h/milliliter…
Cystic Fibrosis · Lung Transplant
Primary: Steady-state Pharmacokinetics of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Stable Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Recipients…
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Healthy Volunteers
Primary: Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AE — 0; 0; 0; 0 Participants
Cystic Fibrosis
Primary: Forced Expiratory Volume — 4 percentage of predicted